25.10.2018, 1091 Zeichen

Valneva: Valneva SE, an Austrian/French commercial stage biotech company focused on developing innovative lifesaving vaccines, announced that the European Medicines Agency (EMA) provided positive feedback onthe Company’s general development approach for its Lyme disease vaccine candidate, VLA15. EMA’s comprehensive scientific advice is largely aligned with previous discussions with theUS Food and Drug Administration (FDA) on the strategy for the VLA15 development andreaffirms the Company’s key development assumptions. Wolfgang Bender, Chief Medical Officer of Valneva commented: “Aligning withboth the EMA and FDA bolsters our confidence in the development strategy for our Lyme disease vaccine candidate. We will continue to work very closely with regulatory authorities as we advance our vaccine, with the aim of protecting people from this often debilitatingdisease.” The Company confirms it expects to enter Phase 2 clinical development at the end of 2018.
Valneva: weekly performance: -8.17%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/10/2018)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1119: ATX dreht am Verfallstag Nachmittag ins Minus, Talk mit Marinomed-CEO und dad.at-Chef nennt Top-Mitarbeiter

Bildnachweis

Aktien auf dem Radar:Semperit, Mayr-Melnhof, CPI Europe AG, EuroTeleSites AG, Polytec Group, Kapsch TrafficCom, Österreichische Post, Wienerberger, FACC, Bajaj Mobility AG, Rosgix, Uniqa, AT&S, CA Immo, Flughafen Wien, Frequentis, Lenzing, Marinomed Biotech, Palfinger, VIG, Wolford, Wolftank-Adisa, Erste Group, Oberbank AG Stamm, RHI Magnesita, DO&CO, Amag, EVN, Telekom Austria.

---